乐心医疗(300562) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥248,679,459.90, representing a 52.93% increase compared to ¥162,605,363.38 in the same period last year[7] - Net profit attributable to shareholders was ¥13,665,579.08, a significant turnaround from a loss of ¥12,098,183.90, marking a 212.96% improvement[7] - The basic earnings per share increased to ¥0.06 from a loss of ¥0.06, reflecting a 200.00% change[7] - Total operating revenue for Q1 2024 reached CNY 248,679,459.90, a significant increase of 52.93% compared to CNY 162,605,363.38 in Q1 2023[27] - Net profit for Q1 2024 was CNY 12,737,408.23, recovering from a net loss of CNY 12,334,521.08 in the same period last year[28] - The company's gross profit margin improved, with operating costs at CNY 233,017,194.97, compared to CNY 176,756,527.35 in Q1 2023, indicating better cost management[27] - Basic earnings per share for Q1 2024 was CNY 0.06, recovering from a loss of CNY 0.06 per share in Q1 2023[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,543,096,887.24, a decrease of 0.86% from ¥1,556,498,078.53 at the end of the previous year[7] - The total assets decreased slightly to CNY 1,543,096,887.24 from CNY 1,556,498,078.53, while total liabilities also decreased to CNY 514,225,609.93 from CNY 532,345,483.50[26] - The company's equity attributable to shareholders rose to CNY 1,046,263,912.41, compared to CNY 1,040,603,601.53 in the previous year[26] Cash Flow - Operating cash flow net amount was -¥16,324,596.58, which is a 22.58% decline compared to -¥13,317,439.03 in the previous year[15] - The company’s cash flow from investing activities was -¥306,496,499.41, a 33.19% increase in outflows compared to -¥230,113,325.71 in the previous year[15] - The cash inflow from operating activities totaled $246,127,581.32, an increase of 9.3% compared to $225,828,559.29 in the previous period[30] - The net cash outflow from operating activities was $16,324,596.58, worsening from a net outflow of $13,317,439.03 in the prior period[30] - Cash inflow from investment activities was $202,903,806.93, significantly up from $58,672,325.83 in the previous period[30] - The net cash outflow from investment activities was $306,496,499.41, compared to a net outflow of $230,113,325.71 in the prior period[30] - The cash inflow from financing activities was $2,000,000.00, while cash outflow totaled $10,998,181.40, leading to a net cash outflow of $8,998,181.40[31] - The ending balance of cash and cash equivalents was $299,245,956.61, slightly up from $298,020,147.54 in the prior period[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,873, with no preferred shareholders having restored voting rights[16] - Major shareholder Pan Weichao holds 33.23% of shares, totaling 72,066,874 shares, with 54,050,155 shares under pledge[16] - The company has a total of 1,311,600 shares held in a repurchase account, representing 0.60% of the total share capital[18] - The number of restricted shares held by executives decreased to 54,708,553 shares after 1,683,194 shares were released from restriction[20] - The company has not disclosed any known relationships among the top shareholders, nor whether they are considered acting in concert under relevant regulations[17] Investment and Expenses - The company reported a significant increase in trading financial assets, rising by 2693.08% to ¥312,852,340.63 due to investments in bank wealth management products[11] - Sales expenses surged by 152.61% to ¥26,501,456.13, primarily due to increased sales commission costs[12] - Investment income increased by 756.66% to ¥2,102,584.04, attributed to gains from foreign exchange settlement contracts[12] - Research and development expenses increased to CNY 27,632,310.25, up from CNY 26,546,810.18, reflecting the company's commitment to innovation[27] - The company reported a significant reduction in financial expenses, with a net financial cost of CNY -1,921,136.53 compared to CNY 3,490,376.81 in the previous year[27] Future Outlook - The company has set performance targets for the stock option incentive plan, aiming for net profits of RMB 50 million in 2024 and RMB 80 million in 2025[21] - The company is focused on enhancing the cohesion and combat effectiveness of its management and core employees through the new incentive plans[21] - The company aims to expand its market presence and enhance product offerings, focusing on new technologies and strategic partnerships[29] Tax and Deferred Assets - Deferred income tax assets increased to CNY 18,150,881.03 from CNY 16,654,044.98, indicating potential future tax benefits[26]